scholarly journals Correlations of Aldehyde dehydrogenase-1 (ALDH1) expression with traditional prognostic parameters and different molecular subtypes of breast carcinoma

2018 ◽  
Vol 91 (2) ◽  
pp. 181-187 ◽  
Author(s):  
Piyabi Sarkar ◽  
Keya Basu ◽  
Pubali Sarkar ◽  
Uttara Chatterjee ◽  
Madhumita Mukhopadhyay ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Breast Carcinoma ◽  
Aldehyde Dehydrogenase ◽  
Molecular Subtypes ◽  
Stem Cell Differentiation ◽  
Tumor Stem Cell ◽  
Prognostic Parameters ◽  
Aldehyde Dehydrogenase 1 ◽  
Aldh1 Expression

Background and aim. Breast cancer, a heterogeneous disease, is the most common cause of cancer-related death in women worldwide. Despite considerable developments in treatment modalities, a subset of patients with advanced-stage breast carcinoma display poor prognosis. Breast cancer heterogeneity and risk of recurrence could be explained with the help of cancer stem cell hypothesis. Stem cells have the capacity to self-renew and differentiate into multiple cell types. Aldehyde dehydrogenase-1 (ALDH1), an enzyme responsible for the oxidation of intracellular aldehydes, contributes to normal and tumor stem cell differentiation. Invasion and metastasis in breast cancer are found to be mediated by a subpopulation of tumor cells which exhibit stem cell-like features and express ALDH1. The aim was to document ALDH1 expression in breast carcinoma and find its association with other clinico-pathologic prognostic parameters.Study design. This was a cross-sectional observational study.Methods. A total of 62 patients with breast carcinoma undergoing mastectomy were included in this study. The tumors were classified into molecular subtypes by assessing immunohistochemical (IHC) expression of ER, PgR, HER2 and Ki-67 according to St. Gallen Consensus Conference 2013. ALDH1 expression was studied by IHC and correlated with clinicoathological parameters.Statistical analysis. Statistical analysis was done using Graph Pad software (Prism 5 version) for Windows 7. A p-value <0.05 was considered statistically significant.Results and analysis. Out of 62 tumors, 35 tumors (56.4%) showed ALDH1 positivity. ALDH1 expression was significantly associated with larger size, lymph node involvement, higher grade, higher stage and HER2+ or triple negative tumors.Conclusion. This study suggests that ALDH1 expression is associated with poor prognostic parameters and aggressive tumor behavior. Larger population-based prospective trials on Indian patients are required to validate these results.

scholarly journals ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Sonar Soni Panigoro ◽  
Dian Kurnia ◽  
Ahmad Kurnia ◽  
Samuel Johny Haryono ◽  
Zafiral Azdi Albar
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Prognostic Factor ◽  
Triple Negative ◽  
Stem Cell Differentiation ◽  
Stem Cell Marker ◽  
Cancer Tissue ◽  
Breast Cancers ◽  
Poor Prognostic Factor ◽  
Aldh1 Expression

Breast cancer is the most common cancer with an increasing incidence in Asia. About 20% of all breast cancers are triple-negative breast cancers (TNBCs). BCSC is a subset of tumor cells that has stem cell-like characteristics, such as a high capacity for self-renewal and tumor initiation, which implies that BCSC may cause aggressiveness of TNBC. ALDH1 has a role in early stem cell differentiation through its function in the oxidation of retinol to retinoic acid, proposed to be a strong candidate for breast cancer stem cells. Various studies have shown that ALDH1 is one of the markers of CSC that can be used as a prognosis indicator because it can be a biological marker for poor prognostic factors in TNBC. This study assessed the prognostic survival rate with a retrospective cohort method in TNBC patients. A total of 54 of 55 patients treated at RSCM were tested for the expression of ALDH1 through an immunohistochemistry assay of breast cancer tissue using ALDH1 staining. Survival analysis was done to obtain the prognostic data of ALDH1. Positive ALDH1 expression was obtained at 38.89% in TNBC patients. One-year survival and three years of survival in TNBC patients with positive ALDH1 expression were 42.9% and 33.3%, respectively. In this study, ALDH1 can be used as a poor survival prognostic factor with HR 2.636 and p value 0.013. The conclusion of this study is that ALDH1 can be used as a poor prognostic factor in TNBC patients although it cannot be an independent prognostic factor.

scholarly journals Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity

2010 ◽  
Vol 12 (10) ◽  
pp. 1024-1033 ◽  
Author(s):  
M. Rasper ◽  
A. Schafer ◽  
G. Piontek ◽  
J. Teufel ◽  
G. Brockhoff ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumor ◽  
Aldehyde Dehydrogenase ◽  
Tumor Stem Cell ◽  
Glioblastoma Cells ◽  
Brain Tumor Stem Cell ◽  
Aldehyde Dehydrogenase 1 ◽  
Cell Capacity

scholarly journals Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer

2009 ◽  
Vol 7 (3) ◽  
pp. 330-338 ◽  
Author(s):  
Feng Jiang ◽  
Qi Qiu ◽  
Abha Khanna ◽  
Nevins W. Todd ◽  
Janaki Deepak ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stem Cell ◽  
Aldehyde Dehydrogenase ◽  
Tumor Stem Cell ◽  
Aldehyde Dehydrogenase 1

Abstract 54: Role of aldehyde dehydrogenase 1 in breast cancer stem cell survival

2010 ◽  
Author(s):  
Min Zhang ◽  
Dale Hogan ◽  
Aramati Bindu Reddy ◽  
Kota Ramana ◽  
Satish Srivastava ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cell Survival ◽  
Aldehyde Dehydrogenase ◽  
Breast Cancer Stem Cell ◽  
Aldehyde Dehydrogenase 1 ◽  
Stem Cell Survival

scholarly journals Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer

BMC Cancer ◽  
2012 ◽  
Vol 12 (1) ◽  
Author(s):  
J Sven D Mieog ◽  
Esther M de Kruijf ◽  
Esther Bastiaannet ◽  
Peter JK Kuppen ◽  
Anita Sajet ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Aldehyde Dehydrogenase ◽  
Stem Cell Marker ◽  
Cancer Stem Cell Marker ◽  
Cell Marker ◽  
Prognostic Role ◽  
Aldehyde Dehydrogenase 1

scholarly journals Characterization of a Stem-like Subpopulation in Basal-like Ductal Carcinoma in Situ (DCIS) Lesions

2013 ◽  
Vol 289 (3) ◽  
pp. 1303-1312 ◽  
Author(s):  
Qinglin Li ◽  
Gabriel Eades ◽  
Yuan Yao ◽  
Yongshu Zhang ◽  
Qun Zhou
Keyword(s):  
Cancer Cells ◽  
Aldehyde Dehydrogenase ◽  
Breast Cancer Cells ◽  
Ductal Carcinoma ◽  
Chemopreventive Agent ◽  
Aldehyde Dehydrogenase 1 ◽  
Aldh1 Expression ◽  
Migration Potential

Previously, we found that basal-like ductal carcinoma in situ (DCIS) contains cancer stem-like cells. Here, we characterize stem-like subpopulations in a model of basal-like DCIS and identify subpopulations of CD49f+/CD24− stem-like cells that possess aldehyde dehydrogenase 1 activity. We found that these cells show enhanced migration potential compared with non-stem DCIS cells. We also found that the chemopreventive agent sulforaphane can target these DCIS stem-like cells, reduce aldehyde dehydrogenase 1 (ALDH1) expression, and decrease mammosphere and progenitor colony formation. Furthermore, we characterized exosomal trafficking of microRNAs in DCIS and found that several microRNAs (miRs) including miR-140, miR-29a, and miR-21 are differentially expressed in exosomes from DCIS stem-like cells. We found that SFN treatment could reprogram DCIS stem-like cells as evidenced by significant changes in exosomal secretion more closely resembling that of non-stem cancer cells. Finally, we demonstrated that exosomal secretion of miR-140 might impact signaling in nearby breast cancer cells.

scholarly journals Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer

Neoplasma ◽  
2014 ◽  
Vol 61 (03) ◽  
pp. 352-362 ◽  
Author(s):  
E. J. KANG ◽  
H. JUNG ◽  
O. H. WOO ◽  
K. H. PARK ◽  
S. U. WOO ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aldehyde Dehydrogenase ◽  
Aldehyde Dehydrogenase 1
Sign in / Sign up

Export Citation Format

Share Document